Literature DB >> 23160330

PARP inhibitors in lung cancer.

David R Spigel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23160330     DOI： 10.1097/JTO.0b013e31826df1eb

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.

Authors:  Benjamin D Leibowitz; Bonnie V Dougherty; Joshua S K Bell; Joshuah Kapilivsky; Jackson Michuda; Andrew J Sedgewick; Wesley A Munson; Tushar A Chandra; Jonathan R Dry; Nike Beaubier; Catherine Igartua; Timothy Taxter
Journal:  BMC Cancer       Date:  2022-05-28       Impact factor: 4.638

Review 2.  Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer.

Authors:  Éilis Russell; Melissa J Conroy; Martin P Barr
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

3.  In Silico Investigation of Potential PARP-1 Inhibitors from Traditional Chinese Medicine.

Authors:  Kuan-Chung Chen; Mao-Feng Sun; Calvin Yu-Chian Chen
Journal:  Evid Based Complement Alternat Med       Date:  2014-04-30       Impact factor: 2.629

4.  Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort.

Authors:  Daniel R Principe; Matthew Narbutis; Regina Koch; Ajay Rana
Journal:  Sci Rep       Date:  2020-11-19       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.